Aclaris' bosakitug misses primary endpoint in Phase 2 atopic dermatitis trial
ACRS•Aclaris Therapeutics said bosakitug missed the primary and secondary endpoints in a Phase 2 trial for moderate-to-severe atopic dermatitis, though it was generally well tolerated. The company also reported progress and plans for several other drug candidates.
1. Trial results and pipeline
Aclaris Therapeutics reported that bosakitug missed the primary and secondary endpoints in a Phase 2 trial for moderate-to-severe atopic dermatitis and was generally well tolerated. The company said its development priorities remain oral kinase inhibitors and the bispecific antibody ATI-052. A Phase 2b trial of oral ITK/JAK3 inhibitor modzatinib in lichen planus has begun; ATI-9494 completed studies supporting an investigational new drug application, with filing expected this quarter; and a Phase 2b trial of ATI-052 in eosinophilic esophagitis is planned for the first quarter of 2027.




